A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Insmed Inc stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 509,439 shares of INSM stock, worth $40 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
509,439
Previous 654,348 22.15%
Holding current value
$40 Million
Previous $43.8 Million 15.17%
% of portfolio
0.09%
Previous 0.11%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$62.0 - $79.01 $8.98 Million - $11.4 Million
-144,909 Reduced 22.15%
509,439 $37.2 Million
Q2 2024

Jul 29, 2024

SELL
$22.0 - $69.71 $7 Million - $22.2 Million
-317,965 Reduced 32.7%
654,348 $43.8 Million
Q1 2024

May 08, 2024

BUY
$25.72 - $29.94 $1.96 Million - $2.29 Million
76,367 Added 8.52%
972,313 $26.4 Million
Q4 2023

Feb 09, 2024

BUY
$23.42 - $31.74 $930,898 - $1.26 Million
39,748 Added 4.64%
895,946 $27.8 Million
Q3 2023

Nov 13, 2023

SELL
$19.86 - $26.93 $167,558 - $227,208
-8,437 Reduced 0.98%
856,198 $21.6 Million
Q2 2023

Aug 08, 2023

SELL
$16.44 - $21.1 $2.45 Million - $3.14 Million
-148,911 Reduced 14.69%
864,635 $18.2 Million
Q1 2023

May 08, 2023

BUY
$16.26 - $21.73 $1.75 Million - $2.33 Million
107,372 Added 11.85%
1,013,546 $17.3 Million
Q4 2022

Feb 09, 2023

BUY
$16.98 - $23.15 $2.38 Million - $3.25 Million
140,273 Added 18.31%
906,174 $18.1 Million
Q3 2022

Nov 10, 2022

BUY
$20.88 - $28.21 $1.9 Million - $2.56 Million
90,905 Added 13.47%
765,901 $16.5 Million
Q2 2022

Aug 04, 2022

BUY
$17.07 - $25.71 $2.41 Million - $3.63 Million
141,005 Added 26.41%
674,996 $13.3 Million
Q1 2022

May 12, 2022

BUY
$20.42 - $28.13 $10.9 Million - $15 Million
533,991 New
533,991 $12.5 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $10.6B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Bnp Paribas Asset Management Holding S.A. Portfolio

Follow Bnp Paribas Asset Management Holding S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bnp Paribas Asset Management Holding S.A., based on Form 13F filings with the SEC.

News

Stay updated on Bnp Paribas Asset Management Holding S.A. with notifications on news.